While Valeant Pharmaceutical executives and hedge fund billionaire and company board member Bill Ackman were getting grilled by US Senators, the company dropped an important filing It turns out that ...
Believe it or not, one of the best-performing healthcare stocks so far this year is none other than Valeant Pharmaceuticals International (NYSE: VRX). Longtime loser Valeant is up around 20% year to ...
Market watchers and Valeant investors have seen no shortage of changes at the company during its storied collapse. Now, the drugmaker is getting a new name to press ahead. After reviewing the names of ...
Bausch Health agreed to pay the SEC $45 million to settle Valeant Pharmaceuticals (former name) accounting fraud schemes. Three former executives, former CEO Michael Pearson, CFO Howard Schiller and ...
Valeant Pharmaceuticals, which fell under withering scrutiny after acquiring the rights to drugs and then drastically raising their prices, is changing its name. The Canadian company said Tuesday that ...
Let's start with the case for buying Valeant. The drugmaker's CEO, Joe Papa, said not long after he took the helm in 2016 that Valeant "is the turnaround opportunity of a lifetime." Based on the ...
Teva announced the launch of generic Syprine, which treats Wilson's disease. Valeant's Syprine and Cuprimine have combined quarterly revenue of $38 million and $29 millon, respectively. Hits to ...
In the high-stakes M&A game, Valeant Pharmaceuticals (VRX) CEO Michael Pearson has shown skill in navigating the acquisition trail. Pearson has made more than 50 buyouts since taking the helm in 2008 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results